Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to $108.5 million.

  • Therapeutics' Liabilities and Shareholders Equity fell 45.69% to $108.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $564.8 million, marking a year-over-year decrease of 39.60%. This contributed to the annual value of $173.3 million for FY2023, which is 34.89% down from last year.
  • As of Q3 2024, Therapeutics' Liabilities and Shareholders Equity stood at $108.5 million, which was down 14.72% from $127.2 million recorded in Q2 2024.
  • In the past 5 years, Therapeutics' Liabilities and Shareholders Equity ranged from a high of $266.2 million in Q4 2022 and a low of $105.9 million during Q1 2021.
  • For the 3-year period, Therapeutics' Liabilities and Shareholders Equity averaged around $192.6 million, with its median value being $199.7 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 77.06% in 2022, then slumped by 45.69% in 2024.
  • Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $119.0 million in 2020, then spiked by 66.96% to $198.6 million in 2021, then spiked by 34.02% to $266.2 million in 2022, then crashed by 34.89% to $173.3 million in 2023, then slumped by 45.69% to $108.5 million in 2024.
  • Its Liabilities and Shareholders Equity was $108.5 million in Q3 2024, compared to $127.2 million in Q2 2024 and $155.8 million in Q1 2024.